

Saturday, November 8, 4:30-6:00 p.m. CT

6:00 p.m.

Adjourn

Oral Abstract Session

Late-Breaking Research Orals - 3

Grand Ballroom C

Moderators: Krzysztof Kiryluk, MD; Laura H. Mariani, MD, MS, FASN

Note: Abstracts will be posted online by November 10, 2025.

4:30 p.m.	SA-OR088 Safety and Efficacy of Anti-CD19/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) Therapy in Pediatric Patients with Refractory Systemic Lupus Erythematosus (SLE): A Preliminary Clinical Study – Hanyan Meng, Chen Zheng, Yi Xie, Qiu-yu Li, Fei Liu, Jingjing Wang, Ming Sun, Enshun Xu, Jianhua Mao
4:42 p.m.	SA-OR089 Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD – Alan S. Yu, Rekha Garg, Keith A. Bellovich, Arnold L. Silva, Fouad T. Chebib, Claire Padgett, Edmund C. Lee, Tania M. Valencia, Timothy L. Kline, Adriana Gregory, Kevin Carroll, Vishal Patel
4:54 p.m.	SA-OR090 Trial to Evaluate and Assess Effects of Comprehensive Kidney Replacement Therapy (KRT)-Directed, Pre-ESKD Education (CoPE) on Home Dialysis Among Veterans (TEACH-VET): Evaluating KRT Decision-Making State (KDS) Outcomes – Ashutosh M. Shukla, Cydney E. Parmar, I. Magaly Freytes, Yi Guo, Huanguang Jia
5:06 p.m.	SA-OR091 Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study – James A. Tumlin, Rajesh Yalavarthy, Dong Ki Kim, Ju young Moon, Inwhee Park, Sung Gyun Kim, Sreedhar A. Mandayam, Frank B. Cortazar, Amanda M. Enstrom, Heather Thomas, Jiahua Li, Yih-Chieh Chen, Stanford L. Peng, Jason L. Sanders, Ogo I. Egbuna, Arvind Madan
5:18 p.m.	SA-OR092 Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study – Muh Geot Wong, Jicheng Lv, Yunfei Bao, Rebecca J. Anderson, Dana Kim, Sana Shan, Michelle A. Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Vlado Perkovic, Hong Zhang, TESTING Trial Steering Committee
5:30 p.m.	AHA/ACC Hypertension Guidelines: What's New for Kidney Diseases? – Vivek Bhalla, MD, FASN